At Microphone 1

Breast Cancer

TAILORx: How to Apply This Landmark Study

Steven E. Vogl, MD  / August 10, 2018

TAILORx changes the configuration of the ball field and the shape of the ball in deciding which women will be recommended chemotherapy after resection of node-negative, hormone receptor–positive breast cancer. TAILORx was presented by Joseph Sparano, MD, at the 2018 ASCO Plenary Session and simu...

Solid Tumors
Prostate Cancer

Should We Treat Rising PSA in Men With Castrate Androgen Levels?

Steven E. Vogl, MD  / May 10, 2018

In rapid succession, the SPARTAN study results were presented at the 2018 Genitourinary Cancers Symposium, the data were published in The New England Journal of Medicine,1 and the drug apalutamide -(Erleada) was approved by the U.S. Food and Drug Administration (FDA) for men with previously treate...

Solid Tumors
Breast Cancer

Extended Duration of Aromatase Inhibitors Need Not Be Very Long

Steven E. Vogl, MD  / April 10, 2018

At the 2017 San Antonio Breast Cancer Symposium (SABCS), Michael Gnant, MD, FACS, of the Medical University of Vienna presented the 9-year median follow-up of a trial looking at the length of extended aromatase inhibitor therapy. At least four other recently presented or published trials have a...

Colorectal Cancer

Duration of Adjuvant Oxaliplatin-Based Therapy for Stage III Colon Cancer

Steven E. Vogl, MD  / March 25, 2018

“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of the Bronx, New York. When he is not in his clinic, he can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. The opinions expr...

Solid Tumors
Breast Cancer

Neratinib Is Approved: Should We Reject It Anyway?

Steven Vogl, MD  / December 25, 2017

The U.S. Food and Drug Administration (FDA) approved 1 year of extended adjuvant neratinib (Nerlynx) after chemotherapy and a year of trastuzumab (Herceptin) for HER2-positive breast cancer this summer on the basis of the ExteNET trial. Many were surprised at the approval, since the evidence of...

WHAT SHOULD PUMA DO?

Steven Vogl, MD  / December 25, 2017

Puma should invest in developing an escalating-dose schedule for neratinib (Nerlynx). If one plans on giving a drug for a year, and starts after finishing a year of effective adjuvant therapy, there is no hurry to begin at full, intolerable doses. Starting at a lower dose and escalating slowly as to...

Breast Cancer

Model Emphasizes Long-Term Risks of Ovarian Ablation Plus Aromatase Inhibitor

Steven E. Vogl, MD  / November 10, 2017

“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. Here Dr. Vo...

Solid Tumors
Breast Cancer

Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value Yet to Be Demonstrated

Steven E. Vogl, MD  / October 10, 2017  / 2017 ASCO Annual Meeting

The ASCO Post issue of June 25, 2017, did an excellent job of summarizing the results and controversy generated by the initial results of the APHINITY trial, reported at the 2017 ASCO Annual Meeting and published simultaneously online in The New England Journal of Medicine.1 With a median follow-up ...

Issues in Oncology

Duration Studies in Oncology Have Often Been Poorly Designed and Analyzed

Steven E. Vogl, MD  / September 25, 2017

The ASCO Post is pleased to introduce “At Microphone 1,” an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings, and often at the microphone where he stands ready with important questions for pre...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.